drugset / Trial / NCT05999994
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Timeline
- Start
- 2020-01-22
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | — | Intravenous |
| Subject | Temozolomide | Small molecule | — | Oral |
| Subject | Vinorelbine | Small molecule | — | Intravenous |